Victoria M. Villaflor, MD

Articles

Clinical Scenario: Metastatic EBV-Positive NPC

September 25th 2024

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.

Clinical Scenario: Locally Recurrent NPC

September 18th 2024

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

September 18th 2024

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

September 11th 2024

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

September 11th 2024

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

September 4th 2024

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

September 4th 2024

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Value of PD-L1 Biomarker in NPC

August 28th 2024

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Overview of the JUPITER and POLARIS-2 Trials

August 28th 2024

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

Current Guidelines for Managing Nasopharyngeal Carcinoma

August 21st 2024

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

August 21st 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Dr. Villaflor on RAVD of Radiotherapy With Induction Chemotherapy in HNSCC

July 21st 2015

Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.